Recombinant proteins are artificially engineered proteins produced by expressing a gene of interest from recombinant DNA in a host system. The recombinant DNA is typically constructed by cloning the target gene into a plasmid vector downstream of a promoter. Upon introduction into a host cell, the plasmid drives expression of the encoded protein using the host’s native protein synthesis machinery.
Across all domains of life, protein synthesis follows a two-step process: transcription of DNA into messenger RNA (mRNA), followed by translation of mRNA into a specific sequence of amino acids that fold into a functional protein.
Since the development of recombinant DNA technology in the 1970s, recombinant proteins have become essential tools across basic research, diagnostics, and therapeutic development. Their use has led to major advancements in biologics, vaccine development, and molecular diagnostics.
The process begins with the identification and synthesis or amplification of the gene encoding the protein of interest. The gene is inserted into an expression vector containing regulatory sequences required for transcription and translation. Protein sequences may be engineered to enhance solubility, expression yield, or stability without altering the protein’s functional domain. These sequence optimizations are especially relevant when producing difficult-to-express targets or proteins prone to aggregation. Alternatively, PCR-based strategies can be used to amplify and modify the DNA of interest in vitro, bypassing the need for initial vector-based cloning. While less commonly used for large-scale production workflows, PCR-based methods are valuable for rapid construct generation or mutagenesis workflows.
In the case of human genes, coding sequences are typically derived from complementary DNA (cDNA) synthesized from mRNA, rather than genomic DNA, to exclude introns and untranslated regulatory regions. This ensures efficient expression in prokaryotic or eukaryotic systems, which are not equipped to process introns.
The choice of host expression system is a critical determinant of protein yield, folding, post-translational modifications, and overall product quality. Each system offers distinct advantages and limitations, and the optimal selection depends on the structural and functional requirements of the target protein.
Mammalian (e.g., CHO, HEK293)
Mammalian cells are the preferred systems for producing proteins requiring native-like post-translational modifications, such as glycosylation or disulfide bond formation. They are essential for the expression of many therapeutic proteins, including monoclonal antibodies and complex receptor proteins.
Bacterial (e.g., E. coli)
E. coli remains widely used due to its rapid growth, low cost, and high expression yields. However, its inability to perform eukaryotic post-translational modifications limits its application for complex or glycosylated proteins.
Yeast (e.g., Pichia pastoris)
Yeast systems combine ease of culture with the ability to perform some eukaryotic modifications. They are scalable and suitable for expressing secreted proteins with simpler glycosylation patterns.
Insect (e.g., Sf9 cells using baculovirus)
Insect cells, via the baculovirus expression vector system (BEVS), are well-suited for expressing complex eukaryotic proteins, particularly when mammalian systems are not required. They offer a balance between scalability, cost, and folding capacity.
Expression of certain recombinant proteins can impose metabolic stress or cytotoxicity on the host cell, which may reduce viability or impair protein production. To address this, inducible promoters and tightly regulated expression systems are often used to control protein expression levels.
Furthermore, functional expression depends not only on the choice of host but also on sequence optimization. Advances in gene optimization algorithms now allow refinement of parameters beyond codon usage, including mRNA secondary structure and transcriptional efficiency. These enhancements are particularly valuable for large, multi-domain, or otherwise difficult-to-express proteins.
For many targets, especially those requiring complex folding or specific modifications, early-stage parallel screening across multiple expression platforms is essential to identify a compatible and scalable production strategy.
Once the expression vector is constructed, it is introduced into the host cells via transformation (for prokaryotic systems) or transfection (for eukaryotic systems). The host cells are cultured under conditions that promote high-level expression of the recombinant protein.
Downstream processing includes cell lysis (if necessary), centrifugation, and chromatographic techniques such as affinity chromatography, ion exchange, or size exclusion to purify the protein to the required specifications. High cell density fermentation and auto-induction media have expanded the scalability of bacterial expression platforms. In E. coli, these approaches allow OD600 values exceeding 10-20 in lab-scale cultures, which significantly boosts overall protein yield.
Recombinant proteins are indispensable in a wide array of biomedical and industrial applications, ranging from therapeutic agents to tools in molecular biology.
Recombinant proteins are foundational to the biopharmaceutical industry, with broad applications across therapeutic areas. They are used to replace deficient proteins, modulate immune responses, and target disease-specific pathways with high specificity and efficacy.
Key classes of therapeutic recombinant proteins include:
Monoclonal antibodies (mAbs): Used in oncology, autoimmune conditions, and infectious diseases for their high target specificity and extended half-life.
Hormones: Such as recombinant human insulin and erythropoietin, used to manage diabetes and anemia, respectively.
Cytokines and growth factors: Including interleukins and granulocyte colony-stimulating factor (G-CSF), which support immune modulation and hematopoietic recovery.
Additional therapeutic classes include chemokines, interferons, colony-stimulating factors, blood clotting factors, thrombolytic enzymes, and tumor necrosis factors. These proteins are used in the treatment of diverse conditions such as Crohn’s disease, multiple sclerosis, myocardial infarction, anemia, and various cancers.
Recombinant proteins are also integral to gene therapy strategies, where engineered proteins are designed to modulate gene function. These may serve as delivery agents, regulatory molecules, or gene-editing components in targeted therapeutic applications.
The development of recombinant human insulin in the late 1970s marked the first successful large-scale application of recombinant technology for therapeutic use. Produced in E. coli, it demonstrated the feasibility of microbial platforms for biologic drug production. Since then, the field has rapidly expanded.
To date, over 130 recombinant proteins have received FDA approval for clinical use, with more than 170 approved globally. Their success is driven not only by therapeutic efficacy but also by development advantages: recombinant proteins tend to exhibit fewer off-target effects than small molecules, and their design and production can be accelerated using well-established expression platforms.
These developments underscore the ongoing expansion of recombinant proteins as a cornerstone of modern drug development.
Recombinant antigens are widely used in in vitro diagnostic (IVD) assays to detect antibodies or pathogens in patient samples. Their high specificity, scalability, and batch-to-batch consistency enhance the reliability of ELISA, lateral flow, and other serological platforms. Non-bioactive recombinant proteins also serve as calibration standards in immunoassays such as Western blotting, ELISA, and gel shift assays, where structural integrity rather than biological function is the critical requirement.
Recombinant proteins serve as reagents for a variety of laboratory applications:
Epitope-tagged proteins for affinity purification or localization studies
Enzymes used in PCR, cloning, or protein digestion
Control antigens and standards in analytical assays
Protein microarrays, where immobilized proteins are exposed to candidate interaction partners such as other proteins, peptides, lipids, or nucleic acids
Recombinant proteins are also widely used as research reagents in experimental systems. These include tagged proteins for affinity purification or imaging, enzymes for molecular biology, and control antigens for analytical assays. In structural and biophysical studies, site-specific labeling of recombinant proteins with isotopic or fluorescent tags enables high-resolution characterization of protein-ligand interactions. Furthermore, recombinant growth factors play a critical role in supporting advanced biological models such as organoids and 3D cell cultures, which are increasingly applied in disease modeling and high-throughput drug screening workflows.
In vivo studies frequently employ recombinant proteins to modulate signaling pathways or mimic disease conditions in animal models. These tools are crucial for identifying therapeutic candidates and validating mechanistic hypotheses in preclinical research.
Native protein extraction from tissues or organisms is limited by low yield, inconsistent quality, and contamination risks. In contrast, recombinant proteins offer several key advantages:
Scalability and Consistency
Recombinant production enables large-scale manufacturing with consistent quality across batches, which is critical for both therapeutic use and assay development.
Purity and Safety
Recombinant expression systems minimize contamination with pathogens or endogenous host proteins, reducing immunogenicity and variability.
Functional Modifications
Proteins can be engineered to include functional domains, fusion tags, or specific mutations to enhance stability, solubility, or binding specificity.
Speed and Cost-Effectiveness
Production timelines can be optimized using well-characterized vectors and expression systems, allowing faster development and reduced cost, particularly in comparison to extraction from biological samples.
Compared to small-molecule drugs, recombinant protein therapeutics are often associated with improved safety profiles due to their high target specificity. Moreover, their development timelines can be shorter, particularly when leveraging platform technologies for expression and purification, making them an attractive strategy in biologics pipelines.
The evolution of transient gene expression (TGE) in mammalian cells has become a key innovation for rapid, high-throughput production of structurally complex proteins. TGE methods are now partially automated, allowing parallel screening of multiple constructs in formats scalable from micrograms to grams, a feature particularly relevant to biopharmaceutical lead optimization and structure-function studies.
Recombinant proteins are critical reagents throughout the antibody discovery and production pipeline.
Recombinant antigens can be designed to include key epitopes, increasing the likelihood of generating antibodies with high specificity. This is particularly useful in the development of monoclonal and bispecific antibodies. Complex membrane proteins, such as GPCRs and ion channels, can be targets in antibody discovery but often require expression in eukaryotic systems. Among these, mammalian platforms have demonstrated robust capabilities for expressing functional, multi-subunit complexes that are not feasible to produce in bacterial systems.
The ability to produce truncated or mutated versions of a protein facilitates epitope mapping and affinity maturation, guiding the development of antibodies with desired binding properties.
Recombinant proteins are frequently used in phage display systems and hybridoma screens to identify antibody clones with optimal binding profiles.
Recombinant expression allows for the generation of engineered antigens and complex antibody formats. These include Fc-fusion proteins, antibody-drug conjugate (ADC) targets, and antigen mimetics for CAR-T cell development.
Biointron provides mammalian and bacterial recombinant protein expression services tailored for the scalable production of complex, functional proteins. The platform is optimized for expressing enzymes, secreted proteins, soluble proteins, and more. Biointron supports clients developing therapeutic antibodies, diagnostic assays, and research-grade proteins.
Biointron offers expression in both CHO-K1 and HEK293 cells for mammalian systems and E. coli for bacterial expression. The mammalian platforms are suitable for proteins requiring glycosylation, disulfide bond formation, or other eukaryotic modifications, while E. coli is appropriate for non-glycosylated proteins, cytoplasmic enzymes, and proteins amenable to refolding or fusion tag-based purification. This flexibility allows clients to match protein characteristics with the most cost-effective and scalable system.
Find out more here: https://www.biointron.com/recombinant-protein-expression/recombinant-protein-expression-in-mammalian-cells.html
References:
Assenberg, R., Wan, P. T., Geisse, S., & Mayr, L. M. (2013). Advances in recombinant protein expression for use in pharmaceutical research. Current Opinion in Structural Biology, 23(3), 393-402. https://doi.org/10.1016/j.sbi.2013.03.008
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020). Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing. Biotechnology Advances, 43, 107552. https://doi.org/10.1016/j.biotechadv.2020.107552
Schütz, A., Bernhard, F., Berrow, N., Buyel, J. F., Ferreira-da-Silva, F., Haustraete, J., van den Heuvel, J., Hoffmann, J.-E., de Marco, A., Peleg, Y., Suppmann, S., Unger, T., Vanhoucke, M., Witt, S., & Remans, K. (2023). A concise guide to choosing suitable gene expression systems for recombinant protein production. STAR Protocols, 4(4), 102572. https://doi.org/10.1016/j.xpro.2023.102572
Artificial intelligence has greatly improved therapeutic antibody development, n……
Antibody affinity is a core metric in immunology and biopharmaceutical science. ……
A roundup of the biggest antibody biotech and pharma deals in December 2025.
The antibody therapeutics landscape continues to evolve rapidly, with 2026 marki……
You can also contact us on the Scientist and Science Exchange marketplaces.
